- Introduction: What Is Coluracetam?
- Chemical Identity & Physical Properties
- Mechanism of Action: The HACU Pathway
- Preclinical Evidence
- Clinical Trial History
- Dosage, Administration & Pharmacokinetics
- Global Market Analysis
- Pricing & Supplier Landscape
- Are There Better Alternatives? Comparative Analysis
- Alternative 1: Alpha-GPC
- Alternative 2: Citicoline (CDP-Choline)
- Alternative 3: Noopept
- Alternative 4: Aniracetam
- Alternative 5: Fasoracetam
- Alternative 6: Bacopa Monnieri
- Alternative 7: Huperzine A
- Alternative 8: Phenylpiracetam
- Comparative Summary & Recommendations
- Stacking Guide
- Safety & Side Effects
- Regulatory Status
- FAQ
- Conclusion
1. Introduction: What Is Coluracetam?
Coluracetam (INN; development code BCI-540; formerly MKC-231) is a synthetic nootropic agent belonging to the racetam family, distinguished by its unique mechanism of action as a high-affinity choline uptake (HACU) enhancer. Unlike first-generation racetams such as Piracetam that lack a clearly defined molecular target, Coluracetam selectively modulates the rate-limiting step of acetylcholine synthesis by potentiating the high-affinity choline transporter (CHT1/SLC5A7).
Originally developed by Mitsubishi Tanabe Pharma Corporation in Japan during the mid-1990s for Alzheimer's disease, the compound failed to reach clinical endpoints for AD and was subsequently in-licensed by BrainCells Inc. in 2006 for investigation in major depressive disorder (MDD) with comorbid generalized anxiety disorder (GAD). A Phase IIa clinical trial in 101 patients reported promising subgroup results, but the data were never published in peer-reviewed literature, and BrainCells Inc. appears to be defunct.
Coluracetam is the only racetam with validated direct CHT1 binding and pathology-dependent HACU enhancement — it is active exclusively in cholinergically impaired neurons, with no detectable effect on normal, unimpaired neurons. This selectivity profile is unmatched by any other compound in the nootropic landscape.
2. Chemical Identity & Physical Properties
The IUPAC name is N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)-2-(2-oxopyrrolidin-1-yl)acetamide. Coluracetam features a tetrahydrofuro-quinoline scaffold — a bioisostere of the 9-amino-tetrahydroacridine class — linked to a 2-pyrrolidinone (pyrrolidone) core characteristic of all racetams. This structural hybrid explains both its cholinergic specificity and its favorable safety profile at low doses.
3. Mechanism of Action: The HACU Pathway
Coluracetam's primary mechanism is the enhancement of high-affinity choline uptake (HACU) — the rate-limiting step in acetylcholine (ACh) synthesis. HACU is mediated by the high-affinity choline transporter CHT1 (encoded by the SLC5A7 gene), which transports choline from the extracellular space into presynaptic cholinergic nerve terminals.
The HACU → ACh Synthesis Cascade
Key Pharmacological Properties
- Pathology-dependent action: Coluracetam significantly increases HACU in hippocampal synaptosomes of AF64A-treated (cholinergically lesioned) rats, but not in normal rats. This means it only activates when cholinergic neurons are impaired — a unique selectivity profile.
- CHT1 binding: Increases HC-3 (hemicholinium-3) binding Bmax by 1.7-fold, indicating increased transporter availability or affinity.
- Vmax enhancement: Increases HACU Vmax by 1.6-fold, meaning the maximum rate of choline transport is boosted by 60%.
- AMPA modulation: Minor positive allosteric modulation of AMPA receptors, contributing to enhanced glutamatergic signaling.
- NMDA neuroprotection: Protects NMDA receptors from glutamate toxicity, with potential relevance for stroke, traumatic brain injury, and neurodegenerative conditions.
- No cholinergic side effects: Unlike AChE inhibitors (e.g., tacrine, donepezil), Coluracetam does not produce tremor, salivation, or hypothermia — even at effective doses.
HACU is the bottleneck of acetylcholine production. Even when choline is abundant, neurons cannot synthesize more ACh than the CHT1 transporter allows. By upregulating CHT1 function, Coluracetam removes this bottleneck — but only in damaged neurons that need it. This is fundamentally different from AChE inhibitors (which prevent ACh breakdown) or choline donors (which increase choline supply).
4. Preclinical Evidence
Coluracetam has been studied extensively in animal models of cholinergic dysfunction, primarily using the AF64A (ethylcholine mustard aziridinium ion) model, which selectively destroys cholinergic neurons in the hippocampus.
| Study | Model | Dose | Key Finding | Reference |
|---|---|---|---|---|
| Bessho et al. (1996) | AF64A rat, Morris water maze | 0.3-3.0 mg/kg p.o. | Reversed learning deficits; no cholinergic side effects (vs. tacrine) | Arzneimittelforschung 46(4):369-73 |
| Murai et al. (1994) | AF64A mouse, working memory | 1-10 mg/kg p.o. | Ameliorated memory deficits & restored hippocampal ACh | J Neural Transm 98(1):1-13 |
| Bessho et al. (2008) | AF64A rat, repeated dosing | Chronic administration | Long-lasting cognitive improvement after repeated dosing | J Neural Transm 115(7):1019-25 |
| Shirayama et al. (2007) | Phencyclidine rat model | Subcutaneous | Reversed PCP-induced behavioral deficits & protected ChAT neurons | Eur Neuropsychopharmacol 17(9):616-26 |
| In vitro (synaptosomes) | Hippocampal synaptosomes | 10-10-10-6 mol/L | Increased HACU in AF64A-treated but not normal rats | Multiple studies |
Development Timeline
5. Clinical Trial History
Phase IIa Trial: MDD with Comorbid GAD (BrainCells Inc., 2010)
The only published (press release only, never peer-reviewed) human clinical trial of Coluracetam was a double-blind, randomized, placebo-controlled Phase IIa study conducted by BrainCells Inc. in 101 patients with major depressive disorder who had failed treatment with at least two antidepressants and also had comorbid generalized anxiety disorder.
| Parameter | Details |
|---|---|
| Trial Design | Double-blind, randomized, placebo-controlled Phase IIa |
| Population | 101 patients with treatment-resistant MDD + comorbid GAD |
| Duration | 6 weeks |
| Dose Regimens | 80 mg once daily (QD) vs. 80 mg three times daily (TID = 240 mg/day) vs. placebo |
| Primary Endpoint | HAM-D (Hamilton Depression Rating Scale) change from baseline |
| TID Result | 36% response rate vs. 19% placebo (p<0.008 in subgroup analysis) |
| QD Result | No statistically significant improvement vs. placebo |
| Safety | Side effect profile similar to placebo; no serious adverse events reported |
| Publication Status | Never published in peer-reviewed literature — known only through company press releases |
| Sponsor Status | BrainCells Inc. appears defunct; compound out-licensed but no active development |
The Phase IIa trial data should be treated with significant skepticism because: (1) results were never published in peer-reviewed literature; (2) the sponsoring company is now defunct; (3) the data are known only through press releases; (4) the trial was exploratory (Phase IIa), not confirmatory; (5) only one human study has ever been conducted. There is no validated clinical use case for Coluracetam in depression or any other condition.
6. Dosage, Administration & Pharmacokinetics
| Parameter | Clinical Trial | Nootropic Research Use |
|---|---|---|
| Daily Dose | 240 mg/day (80 mg × 3) | 5-80 mg per dose, 1-3 times daily |
| Route | Oral | Sublingual (preferred) or oral |
| Onset | Not formally studied | ~30 minutes (peak effectiveness) |
| Half-Life | Not formally studied | ~2-3 hours (estimated) |
| Duration | 6-week trial | ~3 hours per dose |
| Food | With food | With food (lipophilic); some prefer empty stomach |
| Bioavailability | Not formally studied | Limited oral; sublingual strongly preferred |
Administration Guidelines
- Start low: Begin with 5-10 mg sublingually to assess individual sensitivity and neurochemistry response.
- Titrate up: Gradually increase to 20-80 mg per dose based on response and tolerability.
- Frequency: 1-3 times daily due to short half-life; space doses 3-4 hours apart.
- Choline co-supplementation: Non-negotiable. Always pair with Alpha-GPC (300-600 mg) or Citicoline (250-500 mg). Coluracetam increases choline demand; without adequate supply, users experience headaches and brain fog.
- Cycling: Due to limited long-term safety data, consider cycling (e.g., 5 days on, 2 days off) rather than continuous daily use.
7. Global Market Analysis
Market Size & Growth
| Metric | Value | Source |
|---|---|---|
| Global Market Size (2024) | $48.2 million | MarketIntelo |
| Projected Market (2033) | $117.6 million | MarketIntelo |
| CAGR (2024-2033) | 10.2% | MarketIntelo |
| Alternative Estimate (2025) | $0.1 billion | MarketIntelo (Report B) |
| Alternative Projection (2034) | $0.2 billion | MarketIntelo (Report B) |
| Alternative CAGR | 6.5% | MarketIntelo (Report B) |
| Broader Nootropics Market (2024) | $4.98 billion | Datavagyanik |
| Broader Nootropics Projection (2034) | $19.53 billion | Datavagyanik |
| Nootropics CAGR | 14.64% | Datavagyanik |
Market Segmentation
| Segment | Category | Market Share | Growth Rate |
|---|---|---|---|
| Product Type | Powder | 44.7% | Steady |
| Capsules | 32.8% | Fastest growing | |
| Tablets | 15.4% | Moderate | |
| Application | Dietary Supplements | 42.3% | Largest segment |
| Nootropic Products | 31.8% | Growing | |
| Research & Development | 19.4% | Stable | |
| Distribution Channel | Online Stores | 45.6% | 8.2% annual growth (fastest) |
| Pharmacies | 27.4% | Declining | |
| Specialty Stores | 19.3% | Stable | |
| End-User | Adults | Largest group | — |
| Elderly | Second largest | — | |
| Students | Third largest | — |
Regional Distribution
Key Market Drivers
- Aging populations: Global dementia cases climbing 20% yearly, affecting 55+ million people by 2026 — driving demand for cognitive enhancers.
- Nootropic mainstream adoption: Biohacking and cognitive optimization normalized in technology sectors, fitness communities, and student populations.
- E-commerce expansion: Online channels capturing 65.4% of distribution, democratizing access to specialized compounds.
- Capsule preference: 48.2% consumer preference for capsules due to convenience and precise dosing.
- Manufacturing capacity: Over 150 suppliers predominantly in China (e.g., Xi'an Honest BioEngr, Conscientia Industrial), with cGMP expansions matching global API growth.
- Energy-efficient synthesis: New manufacturing processes cutting costs 10-15%, enabling 20% volume increases.
Major Market Participants
| Company | Role | Market Position |
|---|---|---|
| Merck KGaA | Raw material supplier & reference standards | Dominant participant |
| BASF SE | Chemical manufacturing | Major supplier |
| Lonza Group AG | Contract manufacturing | Key CDMO |
| Tokyo Chemical Industry (TCI) | Research-grade supply | Specialized supplier |
| Cayman Chemical | Research biochemicals | Research supplier |
| Thermo Fisher Scientific | Research chemicals (Alfa Aesar) | Broad catalog |
| Santa Cruz Biotechnology | Research biochemicals | Niche supplier |
| Carbosynth Ltd | Specialty carbohydrates & biochemicals | Niche supplier |
8. Pricing & Supplier Landscape
Price Tiers by Quantity
| Quantity | Price Range | Price per Gram | Supplier Type |
|---|---|---|---|
| 5 mg | $30 | $6,000/g | Research biochemical (AbMole) |
| 10 mg | $40 | $4,000/g | Research biochemical |
| 50 mg | $70 | $1,400/g | Research biochemical |
| 100 mg | $90-$350 | $900-$3,500/g | Research supplier |
| 100 g | $350 | $3.50/g | Bulk manufacturer (Dingwang Tech) |
| 1 kg | $2,500 | $2.50/g | Bulk manufacturer |
| 1 kg (wholesale) | $10/kg | $0.01/g | Myland Pharm (ECHEMI) |
| 25 kg drum | $2,300-$2,500/kg | $2.30-$2.50/g | Industrial supplier |
The massive price range ($0.01/g to $6,000/g) reflects the difference between research-grade reference standards (milligram quantities with full analytical documentation) and bulk industrial supply (kilogram quantities at 99% purity). For research institutions, expect $90-$350 for 100 mg with COA. For bulk manufacturing, $2,500-$10,000 per kilogram at 99%+ purity is typical.
Supplier Quality Checklist
9. Are There Better Alternatives? Comparative Analysis
This is the central question for researchers and formulators evaluating Coluracetam: does the market offer better alternatives? We analyze eight compounds that target the same or overlapping cognitive pathways, comparing them across efficacy, evidence quality, safety, cost, legality, and unique advantages.
Quick Comparison Matrix
| Compound | Mechanism | Dose | Clinical Evidence | Legal Status (US) | Monthly Cost | vs. Coluracetam |
|---|---|---|---|---|---|---|
| Coluracetam | HACU enhancer (CHT1) | 20-80 mg | 1 Phase IIa (unpublished) | Unscheduled, not DSHEA | $20-40 | — |
| Alpha-GPC | Choline donor (BBB-crossing) | 300-600 mg | Multiple RCTs, meta-analyses | DSHEA-compliant | $15-30 | Better evidence |
| Citicoline | Choline + uridine donor | 250-500 mg | Extensive RCTs (24-month safety) | DSHEA-compliant | $15-25 | Better safety |
| Noopept | BDNF/NGF + cholinergic | 10-30 mg | Russian RCTs (cognitive) | Unscheduled, not DSHEA | $20-30 | More potent |
| Aniracetam | AMPA modulator + anxiolytic | 750-1500 mg | European clinical use | Unscheduled, not DSHEA | $30-40 | Different pathway |
| Fasoracetam | GABA-B upregulation + cholinergic | 100-400 mg | ADHD Phase II/III trials | Unscheduled, not DSHEA | $30-45 | Different pathway |
| Bacopa Monnieri | ACh modulation + antioxidant | 300-600 mg | Multiple RCTs (84-day studies) | DSHEA-compliant | $15-25 | Better evidence |
| Huperzine A | AChE inhibitor | 50-200 mcg | Chinese RCTs (Alzheimer's) | DSHEA-compliant | $10-20 | Better evidence |
| Phenylpiracetam | Dopamine/NE + stimulant | 100-200 mg | Russian clinical use | Unscheduled, WADA-banned | $35-45 | Different purpose |
10. Alternative 1: Alpha-GPC (L-alpha-glycerylphosphorylcholine)
Mechanism: Hydrolyzed in the gut and brain to release free choline, which crosses the BBB via CHT1 and is used for ACh synthesis. Also provides glycerophosphate for phospholipid synthesis via the Kennedy pathway. Enhances HACU and supports muscarinic/nicotinic receptor function.
Dose: 300-600 mg daily; up to 1200 mg for clinical Alzheimer's use. High oral bioavailability.
Half-life: 4-6 hours (longer than Coluracetam's 2-3 hours).
Why it may be better: Alpha-GPC is the most bioavailable oral choline source, with multiple RCTs, meta-analyses, and clinical use in Europe for Alzheimer's disease. A 2025 meta-analysis confirmed it outperforms Citicoline across most cognitive domains, producing nearly double the plasma choline increase. It is DSHEA-compliant, widely available, and far less expensive per dose. It directly increases choline supply, which complements Coluracetam's enhancement of choline uptake.
Where Coluracetam still wins: Alpha-GPC does not selectively target damaged neurons. It raises choline globally, whereas Coluracetam's pathology-dependent HACU enhancement is active only where it's needed — potentially reducing systemic side effects.
Safety concerns: High chronic doses may be associated with increased stroke risk (epidemiological, not confirmed causally). Common side effects: headache, heartburn, dizziness.
11. Alternative 2: Citicoline (CDP-Choline)
Mechanism: Provides both choline and cytidine (converted to uridine in humans). Choline feeds ACh synthesis; uridine supports phosphatidylcholine synthesis for neuronal membrane repair. Also increases dopamine receptor density and supports dopamine synthesis via the uridine pathway.
Dose: 250-500 mg daily. Clinical doses up to 1000 mg.
Why it may be better: Citicoline offers broader neuroprotection than Coluracetam through membrane phospholipid synthesis. It has an excellent safety record studied through 24 months of continuous use. It is used as a pharmaceutical (Cognizin) in Europe and Japan. Its dual mechanism (ACh + dopamine + membrane) provides more complete cognitive support. It is DSHEA-compliant and costs less per dose.
Where Coluracetam still wins: Citicoline does not directly enhance HACU or CHT1 function. It provides the raw materials for ACh synthesis but does not upregulate the transporter that controls the rate-limiting step.
Synergy: Many experienced users take both Alpha-GPC (150 mg) and Citicoline (250 mg) at half-doses to access both choline delivery pathways simultaneously.
12. Alternative 3: Noopept (N-phenylacetyl-L-prolylglycine ethyl ester)
Mechanism: Peptide-derived nootropic that boosts brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) — neurotrophic support that Coluracetam does not provide. Also modulates cholinergic and glutamatergic transmission.
Dose: 10-30 mg daily (ultra-potent — approximately 1000× Piracetam by weight).
Onset: 10-15 minutes (faster than Coluracetam).
Why it may be better: Noopept offers neuroplasticity benefits (BDNF/NGF upregulation) that Coluracetam completely lacks. It works at even lower doses, and Russian clinical trials support its use for cognitive enhancement and post-traumatic cognitive recovery. Users report enhanced visual clarity and memory when combined with Coluracetam — suggesting complementary rather than competing mechanisms.
Where Coluracetam still wins: Noopept does not directly enhance HACU. Its cholinergic effects are indirect. Coluracetam's selective CHT1 modulation remains unique.
Safety: Limited long-term data; headache risk if taken without choline.
13. Alternative 4: Aniracetam
Mechanism: Fat-soluble racetam that modulates AMPA receptors (positive allosteric modulation) and serotonin pathways, producing both cognitive enhancement and anxiolytic effects.
Dose: 750-1500 mg daily (with food for absorption).
Duration: 5-7 hours (longer than Coluracetam).
Why it may be better: Aniracetam offers anxiolytic benefits that Coluracetam lacks, making it better suited for stress-related cognitive impairment. It has more European clinical experience and is better tolerated by users sensitive to pure cholinergic stimulation. Popular for creative work and social situations.
Where Coluracetam still wins: Aniracetam does not enhance HACU. Its mechanism is completely different (AMPA modulation), so it addresses a different aspect of cognitive function. The two are complementary, not competitive — the Coluracetam + Aniracetam stack is a popular and effective combination.
14. Alternative 5: Fasoracetam (NS-105)
Mechanism: Upregulates GABA-B receptors and modulates cholinergic, glutamatergic, and GABAergic systems. Being developed as a potential ADHD treatment.
Dose: 100-400 mg daily.
Why it may be better: Fasoracetam has completed Phase II/III clinical trials for ADHD — giving it more recent and relevant clinical development than Coluracetam. It may help restore GABA sensitivity, offering anxiety relief through a completely different mechanism. It addresses attention deficits more directly than Coluracetam.
Where Coluracetam still wins: Fasoracetam does not enhance HACU or selectively target cholinergic impairment. Its primary value is in GABA modulation, not acetylcholine optimization.
15. Alternative 6: Bacopa Monnieri
Mechanism: Natural adaptogen that modulates acetylcholine release, binds muscarinic receptors, enhances choline acetyltransferase (ChAT) activity, and reduces cortisol. Hits multiple cognitive pathways overlapping with racetam mechanisms.
Dose: 300-600 mg daily (standardized to 50% bacosides).
Why it may be better: Bacopa is the closest legal, DSHEA-compliant alternative to racetam-style memory enhancement. A comprehensive 2024 RCT showed significant improvements in verbal memory, spatial memory, working memory, concentration, alertness, reasoning, and mental flexibility after 84 days of consistent use. It is natural, legal, widely available, and has an excellent safety profile for long-term daily use.
Where Coluracetam still wins: Bacopa's effects are slow-onset (requires 8-12 weeks for full benefit) and less acutely noticeable. Coluracetam provides more rapid, targeted cholinergic enhancement. Bacopa does not enhance HACU specifically.
Safety: Well-tolerated; occasional mild GI upset. No serious adverse effects reported in clinical trials.
16. Alternative 7: Huperzine A
Mechanism: Potent, reversible acetylcholinesterase (AChE) inhibitor isolated from Huperzia serrata. Prevents ACh breakdown rather than enhancing its synthesis.
Dose: 50-200 mcg daily (micrograms — extremely potent).
Why it may be better: Huperzine A has Chinese RCTs supporting its use in Alzheimer's disease and is DSHEA-compliant as a natural extract. It is one of the most potent natural cognitive enhancers available. Its AChE inhibition produces a different but complementary effect to HACU enhancement — one increases ACh production, the other prevents its breakdown.
Where Coluracetam still wins: Huperzine A inhibits ACh breakdown globally (not selectively in damaged neurons), which can lead to cholinergic side effects at higher doses (nausea, sweating, bradycardia). Coluracetam's pathology-dependent selectivity offers a cleaner pharmacological profile. Also, Huperzine A does not upregulate CHT1 or enhance HACU.
Caution: Should not be combined with prescription AChE inhibitors (donepezil, rivastigmine) without medical supervision.
17. Alternative 8: Phenylpiracetam
Mechanism: Phenyl group addition to Piracetam; modulates dopamine and norepinephrine transporters. Potent psychostimulant with cognitive enhancement.
Dose: 100-200 mg daily.
Why it may be better: Phenylpiracetam offers both mental and physical stimulation — useful for energy, motivation, and athletic performance. Developed in Russia for cosmonauts on long space missions. Faster onset and more noticeable acute effects than Coluracetam.
Where Coluracetam still wins: Phenylpiracetam is a WADA-prohibited substance in competitive sports and is not suitable for users seeking calm, non-stimulatory cognitive enhancement. Tolerance builds rapidly with daily use. It does not enhance HACU. The two compounds serve fundamentally different purposes — Phenylpiracetam is a stimulant, Coluracetam is a cholinergic optimizer.
18. Comparative Summary & Recommendations
By Use Case: Which Compound Should You Choose?
| Goal | Best Choice | Runner-Up | Rationale |
|---|---|---|---|
| Maximum acetylcholine elevation | Alpha-GPC | Coluracetam + Alpha-GPC stack | Alpha-GPC provides the most bioavailable choline; Coluracetam enhances its uptake |
| Long-term neuroprotection | Citicoline | Bacopa Monnieri | Membrane support, dopamine, 24-month safety data |
| Neuroplasticity & BDNF | Noopept | Bacopa Monnieri | Only compounds with proven BDNF/NGF upregulation |
| Anxiety + cognition | Aniracetam | Fasoracetam | AMPA modulation with anxiolytic effects |
| Legal, DSHEA-compliant | Bacopa Monnieri | Alpha-GPC / Citicoline | Natural, legal, well-researched |
| Cholinergic impairment research | Coluracetam | Huperzine A | Only compound with pathology-dependent HACU enhancement |
| Treatment-resistant depression research | Coluracetam | Fasoracetam | Phase IIa data (unpublished) in MDD/GAD; unique cholinergic-mood link |
| Visual enhancement | Coluracetam | Noopept | Users consistently report enhanced color vision and visual acuity |
| Budget-conscious | Bacopa Monnieri | Alpha-GPC | Lowest cost per effective dose with strongest evidence |
| Stimulation + cognition | Phenylpiracetam | Caffeine + L-Theanine | Only choice for combined mental/physical energy |
Overall Verdict
Coluracetam occupies a unique niche that no other compound fully replicates: pathology-dependent HACU enhancement via CHT1 potentiation. For researchers studying cholinergic dysfunction, treatment-resistant depression, or visual processing enhancement, it remains the only compound with this specific mechanism.
However, for most practical cognitive enhancement purposes, better alternatives exist: Alpha-GPC and Citicoline offer superior evidence, safety, legality, and cost-effectiveness for cholinergic support. Noopept adds neurotrophic benefits. Bacopa Monnieri is the best legal, natural option. Coluracetam is best understood as a specialized research tool rather than a first-line cognitive enhancer.
19. Stacking Guide
The Non-Negotiable Stack Partner
Coluracetam supercharges your brain's ability to absorb choline. Without adequate choline supply, you get headaches instead of cognitive benefits. Always pair with:
- Alpha-GPC: 300-600 mg — most bioavailable choline source
- OR Citicoline: 250-500 mg — adds neuroprotective benefits
Synergistic Combinations
| Stack | Dose | Benefit |
|---|---|---|
| Coluracetam + Alpha-GPC | 20-80 mg + 300-600 mg | HACU enhancement + choline supply (non-negotiable base) |
| Coluracetam + Aniracetam | 20-80 mg + 750-1500 mg | Enhanced focus + reduced anxiety (complementary mechanisms) |
| Coluracetam + Noopept | 20-80 mg + 10-20 mg | Enhanced visual clarity + BDNF/NGF neurotrophic support |
| Coluracetam + L-Theanine + Caffeine | 20-80 mg + 100-200 mg + 100 mg | Clean, focused productivity stack |
| Coluracetam + Bacopa Monnieri | 20-80 mg + 300-600 mg | Acute HACU boost + long-term memory consolidation |
What to Avoid
- Multiple heavy cholinergics: Don't stack Coluracetam with high-dose Alpha-GPC + Huperzine A + another racetam simultaneously. Excess acetylcholine causes headaches, irritability, jaw tension, and brain fog.
- Anticholinergic medications: Certain antipsychotics, diphenhydramine (Benadryl), some Parkinson's drugs directly counteract Coluracetam.
- AChE inhibitors: Combining with donepezil or rivastigmine could amplify cholinergic effects excessively.
- High-dose stimulants: Can produce an unpleasant overstimulated feeling when combined with cholinergic enhancement.
20. Safety & Side Effects
Reported Side Effects
| Side Effect | Frequency | Cause | Management |
|---|---|---|---|
| Headache | Common (especially first week) | Choline depletion from increased HACU | Add Alpha-GPC 300-600 mg or Citicoline 250-500 mg |
| Fatigue / brain fog | Common at high doses | Excessive cholinergic activity | Reduce dose; ensure adequate choline |
| Mild nausea | Occasional | Dose-dependent, transient | Take with food; reduce dose |
| Dry mouth | Occasional | Cholinergic modulation | Hydrate; typically resolves with continued use |
| Daytime sleepiness | Uncommon | Paradoxical response at higher doses | Reduce dose; avoid daytime dosing |
| Anxiety / mood instability | Rare | Individual neurochemistry variation | Discontinue use; not suitable for this user |
| Suicidal ideation | Very rare (1 trial participant) | Unknown; possible cholinergic-mood interaction | Discontinue immediately; seek medical attention |
No formal clinical safety studies have been published. The Phase IIa trial reported a side-effect profile similar to placebo, but this was a small (n=101), short (6-week), unpublished study. Long-term safety data are completely absent. Coluracetam should be avoided during pregnancy and breastfeeding — there is zero safety data for these populations.
21. Regulatory Status
| Jurisdiction | Status | Details |
|---|---|---|
| United States | Not FDA-approved; unscheduled | Not a controlled substance. Not DSHEA-compliant (not marketed as supplement before 1994, not found in food). Cannot be legally sold as a dietary supplement or medicine. Available as research chemical. |
| Australia | Schedule 4 (Rx only) | Prescription-only medication. Not available over-the-counter. |
| European Union | No formal approval | Not approved by EMA. Research chemical status. Individual member states may have additional restrictions. |
| United Kingdom | No formal approval | Research chemical status. Not licensed as a medicine. |
| Canada | No formal approval | Not licensed by Health Canada. Research chemical status. |
| Japan | Discontinued development | Originally developed by Mitsubishi Tanabe; no current approval for any indication. |
| WADA / Sports | Not prohibited | Unlike Phenylpiracetam, Coluracetam is not on the WADA Prohibited List. |
Racetams have largely disappeared from reputable US supplement vendors due to FDA enforcement, particularly following the Centera Bioscience (formerly Nootropics Depot's parent company) DOJ prosecution in 2023-2024. Reputable vendors have stopped carrying racetams entirely. Coluracetam is increasingly available only from overseas research chemical suppliers, which raises quality, purity, and legal import concerns.
22. Frequently Asked Questions
Coluracetam (MKC-231, BCI-540) is a racetam-family nootropic that enhances high-affinity choline uptake (HACU) — the rate-limiting step in acetylcholine synthesis. It binds to the choline transporter CHT1 and increases the Vmax of choline transport by 1.6-fold, but only in cholinergically impaired neurons, not in healthy ones. This pathology-dependent mechanism makes it unique among racetams. It was originally developed by Mitsubishi Tanabe Pharma for Alzheimer's disease and later studied by BrainCells Inc for major depressive disorder with comorbid anxiety.
Coluracetam is not FDA-approved for any medical use in the United States and is not classified as a dietary supplement under DSHEA. It is unscheduled (not a controlled substance) but cannot be legally sold as a supplement or medicine. In Australia, it is Schedule 4 (prescription only). No formal approval exists in the EU, UK, or Canada. It is available from research chemical suppliers for laboratory and analytical purposes. Always verify local regulations before purchasing or importing.
In the Phase IIa clinical trial by BrainCells Inc, the effective dose was 240 mg/day (80 mg three times daily). For nootropic research purposes, typical doses range from 5-80 mg per dose, taken 1-3 times daily. Sublingual administration is preferred for higher bioavailability. The compound has a relatively short half-life of 2-3 hours. It is recommended to start with a low dose (5-10 mg sublingually) to assess individual sensitivity. Coluracetam should be taken with a choline source (Alpha-GPC 300-600 mg or Citicoline 250-500 mg) to prevent headaches from choline depletion.
Several alternatives may be preferable depending on the goal. Alpha-GPC (300-600 mg) provides more readily available choline with far more clinical evidence. Citicoline (250-500 mg) adds neuroprotective benefits through the uridine pathway. Noopept (10-30 mg) offers BDNF/NGF neurotrophic support that Coluracetam lacks. Aniracetam (750-1500 mg) provides AMPA modulation with anxiolytic effects. For those seeking legal, DSHEA-compliant options, Bacopa Monnieri and Alpha-GPC are the closest alternatives targeting the same cholinergic pathways. Coluracetam's unique advantage is its pathology-dependent HACU enhancement — no other compound replicates this specific mechanism.
The Phase IIa clinical trial reported a side effect profile similar to placebo. Common side effects include headache (typically from choline depletion, resolved by supplementing Alpha-GPC or Citicoline), fatigue, and brain fog at higher doses. Less commonly reported are mild nausea, dry mouth, and daytime sleepiness. Rare reports include paradoxical anxiety or mood instability. One clinical trial participant reported suicidal ideation. No formal clinical safety studies have been published. Coluracetam should be avoided during pregnancy and breastfeeding due to zero safety data. It should not be combined with anticholinergic medications or cholinesterase inhibitors like donepezil.
The global Coluracetam market was valued at approximately $48.2 million in 2024 and is projected to reach $117.6 million by 2033, growing at a CAGR of 10.2%. Alternative estimates place the 2025 market at $0.1 billion reaching $0.2 billion by 2034 at 6.5% CAGR. Asia Pacific dominates with 38.5% revenue share, followed by North America at 32.2%. Dietary supplements represent 42.3% of applications, with online stores commanding 45.6% of distribution. The broader nootropics market is projected to grow from $4.98 billion in 2024 to $19.53 billion by 2034 at 14.64% CAGR.
Yes, but with important caveats. The non-negotiable stack partner is a choline source — Alpha-GPC (300-600 mg) or Citicoline (250-500 mg) — because Coluracetam increases choline demand. Synergistic combinations include Coluracetam + Aniracetam (750-1500 mg) for focus plus anxiety reduction, and Coluracetam + Noopept (10-20 mg) for enhanced visual clarity and memory. Avoid stacking with multiple heavy cholinergic compounds simultaneously (e.g., high-dose Alpha-GPC + Huperzine A + another racetam), as excess acetylcholine causes headaches, irritability, jaw tension, and brain fog. Also avoid combining with anticholinergic medications.
For in vitro screening and analytical method development, Research Grade (≥98% purity, verified by HPLC) is sufficient. For animal studies and in vivo pharmacology, Preclinical Grade (≥99% purity) is recommended. For clinical trial materials or IND submissions, GMP/IND Grade (≥99.5% purity) is mandatory. Essential documentation should include: Certificate of Analysis (COA) with batch-specific data, HPLC chromatogram, NMR spectra (1H and 13C), mass spectrometry data, heavy metals test (ICP-MS), and residual solvents report (GC-MS). Coluracetam (CAS 135463-81-9) should be stored at -20°C as powder.
23. Conclusion
Coluracetam is a scientifically fascinating compound that occupies a genuinely unique position in the nootropic landscape. Its pathology-dependent HACU enhancement via CHT1 potentiation is unmatched by any other compound — making it an invaluable research tool for studying cholinergic dysfunction, treatment-resistant depression, and visual processing.
Key Takeaways
- Unique mechanism: Coluracetam is the only racetam with validated CHT1 binding and pathology-dependent HACU enhancement — active exclusively in impaired neurons.
- Limited clinical evidence: Only one Phase IIa trial (unpublished, n=101) has been conducted. Results suggested benefit for MDD/GAD but must be treated with significant skepticism.
- Growing market: Global market valued at $48.2M (2024), projected to reach $117.6M by 2033 at 10.2% CAGR, driven by aging populations and nootropic adoption.
- Better alternatives exist for most use cases: Alpha-GPC and Citicoline offer superior evidence, safety, legality, and cost for cholinergic support. Noopept adds neurotrophic benefits. Bacopa Monnieri is the best legal alternative.
- Coluracetam remains irreplaceable for: HACU/cholinergic impairment research, visual enhancement studies, and treatment-resistant depression investigation.
- Regulatory headwinds: FDA enforcement has made racetams increasingly difficult to source from reputable US vendors. Coluracetam is not DSHEA-compliant and remains a research chemical.
For researchers studying cholinergic dysfunction or mood disorders, Coluracetam is an essential tool with a mechanism no other compound replicates. For formulators seeking legal, evidence-based cognitive enhancement ingredients, Alpha-GPC, Citicoline, and Bacopa Monnieri are superior choices. For experienced nootropic users who have already tried established racetams, Coluracetam offers a genuinely different mechanism and unique visual/mood benefits — but should not be a first-line choice.
Coluracetam (MKC-231, BCI-540) is an unapproved research chemical not evaluated or approved by the FDA, EMA, or any regulatory authority for any therapeutic use. It is intended solely for in vitro laboratory research, preclinical studies, and analytical purposes. This article is for informational and educational purposes only and does not constitute medical advice, treatment recommendation, or endorsement of any compound for human use. Always consult qualified regulatory and legal professionals before purchasing, importing, or using research chemicals.
Need High-Purity Coluracetam for Research?
NutraBiotech provides Coluracetam (CAS 135463-81-9) and other research-grade nootropic compounds with full COA documentation, HPLC purity verification (≥98%), and batch-specific testing. Available in gram to kilogram quantities for laboratory research.
Request a Quote